These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 19026455)

  • 101. Immunogenicity Risk Profile of Nanobodies.
    Ackaert C; Smiejkowska N; Xavier C; Sterckx YGJ; Denies S; Stijlemans B; Elkrim Y; Devoogdt N; Caveliers V; Lahoutte T; Muyldermans S; Breckpot K; Keyaerts M
    Front Immunol; 2021; 12():632687. PubMed ID: 33767701
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Nanobodies as efficient drug-carriers: Progress and trends in chemotherapy.
    Panikar SS; Banu N; Haramati J; Del Toro-Arreola S; Riera Leal A; Salas P
    J Control Release; 2021 Jun; 334():389-412. PubMed ID: 33964364
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Expression Cloning and Production of Human Heavy-Chain-Only Antibodies from Murine Transgenic Plasma Cells.
    Drabek D; Janssens R; de Boer E; Rademaker R; Kloess J; Skehel J; Grosveld F
    Front Immunol; 2016; 7():619. PubMed ID: 28066429
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Retroviral transduction of fluonanobody and the variable domain of camelid heavy-chain antibodies to chicken embryonic cells.
    Rajabibazl M; Rasaee MJ; Forouzandeh M; Rahimpour A
    Iran J Immunol; 2013 Dec; 10(4):247-58. PubMed ID: 24375066
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Nanobody-based CTLA4 inhibitors for immune checkpoint blockade therapy of canine cancer patients.
    Marable J; Ruiz D; Jaiswal AK; Bhattacharya R; Pantazes R; Agarwal P; Suryawanshi AS; Bedi D; Mishra A; Smith BF; Sandey M
    Sci Rep; 2021 Oct; 11(1):20763. PubMed ID: 34675296
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Nanobodies.
    Gibbs WW
    Sci Am; 2005 Aug; 293(2):78-83. PubMed ID: 16053141
    [No Abstract]   [Full Text] [Related]  

  • 107. Immunization of Alpacas (Lama pacos) with Protein Antigens and Production of Antigen-specific Single Domain Antibodies.
    Chow KM; Whiteheart SW; Smiley JR; Sharma S; Boaz K; Coleman MJ; Maynard A; Hersh LB; Vander Kooi CW
    J Vis Exp; 2019 Jan; (143):. PubMed ID: 30741259
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Nanobodies and Cancer: Current Status and New Perspectives.
    Allegra A; Innao V; Gerace D; Vaddinelli D; Allegra AG; Musolino C
    Cancer Invest; 2018 Apr; 36(4):221-237. PubMed ID: 29658806
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Small nanobody drugs win big backing from pharma.
    Williams SC
    Nat Med; 2013 Nov; 19(11):1355-6. PubMed ID: 24202374
    [No Abstract]   [Full Text] [Related]  

  • 110. [Single-domain antibody - advances in research and application].
    Kang X; Cao J; Zhang B; Yuan Q
    Sheng Wu Gong Cheng Xue Bao; 2018 Dec; 34(12):1974-1984. PubMed ID: 30584708
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Reshaping nanobodies for affinity purification on protein a.
    Crauwels M; Van Vaerenbergh N; Kulaya NB; Vincke C; D'Huyvetter M; Devoogdt N; Muyldermans S; Xavier C
    N Biotechnol; 2020 Jul; 57():20-28. PubMed ID: 32001339
    [TBL] [Abstract][Full Text] [Related]  

  • 112. First report of a chemokine from camelids: Dromedary CXCL8 is induced by poxvirus and heavy metal toxicity.
    Premraj A; Aleyas AG; Nautiyal B; Rasool TJ
    Dev Comp Immunol; 2024 Dec; 161():105261. PubMed ID: 39241936
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Generation of glycan-specific nanobodies.
    Khilji SK; Goerdeler F; Frensemeier K; Warschkau D; Lühle J; Fandi Z; Schirmeister F; Chen ZA; Turak O; Mallagaray A; Boerno S; Timmermann B; Rappsilber J; Seeberger PH; Moscovitz O
    Cell Chem Biol; 2022 Aug; 29(8):1353-1361.e6. PubMed ID: 35705094
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Single-cell 5' RNA sequencing of camelid peripheral B cells provides insights into cellular basis of heavy-chain antibody production.
    Yi L; Guo X; Liu Y; Jirimutu ; Wang Z
    Comput Struct Biotechnol J; 2024 Dec; 23():1705-1714. PubMed ID: 38689719
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Analytical chemistry: cause for a llama.
    Webb R
    Nature; 2006 May; 441(7090):169. PubMed ID: 16688166
    [No Abstract]   [Full Text] [Related]  

  • 116. Reporter-nanobody fusions (RANbodies) as versatile, small, sensitive immunohistochemical reagents.
    Yamagata M; Sanes JR
    Proc Natl Acad Sci U S A; 2018 Feb; 115(9):2126-2131. PubMed ID: 29440485
    [TBL] [Abstract][Full Text] [Related]  

  • 117. (1)H, (13)C and (15)N assignments of a camelid nanobody directed against human alpha-synuclein.
    Vuchelen A; O'Day E; De Genst E; Pardon E; Wyns L; Dumoulin M; Dobson CM; Christodoulou J; Hsu ST
    Biomol NMR Assign; 2009 Dec; 3(2):231-3. PubMed ID: 19763886
    [TBL] [Abstract][Full Text] [Related]  

  • 118. A comprehensive comparison between camelid nanobodies and single chain variable fragments.
    Asaadi Y; Jouneghani FF; Janani S; Rahbarizadeh F
    Biomark Res; 2021 Dec; 9(1):87. PubMed ID: 34863296
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Discrete analysis of camelid variable domains: sequences, structures, and in-silico structure prediction.
    Melarkode Vattekatte A; Shinada NK; Narwani TJ; Noël F; Bertrand O; Meyniel JP; Malpertuy A; Gelly JC; Cadet F; de Brevern AG
    PeerJ; 2020; 8():e8408. PubMed ID: 32185102
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Unique aspects of adaptive immunity in camelids and their applications.
    Kulkarni SS; Falzarano D
    Mol Immunol; 2021 Jun; 134():102-108. PubMed ID: 33751993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.